Events & Presentations

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific advisory board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Analyst coverage
Financial reports
Financial calendar
Events & Presentations2022
2022
10 December 2022Upcoming
64th American Society of Hematology Annual Meeting
Updated results from the Phase 2 ADVANCE II clinical trial will be presented in an oral presentation on December 12. In addition, the company will present immunomonitoring data in a separate poster presentation on December 10.  
Learn more
30 November 2022Upcoming
Key opinion leader event on immunotherapy for maintenance treatment of Acute Myeloid Leukemia patients in remission
Mendus will host a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients. The event will feature two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital.
Learn more
24 November 2022Previous
Redeye Life Science Day
CEO Erik Manting will participate. A pre-recorded company presentation will be made available by the conference organizer prior to the event.
Learn more
15 November 2022Previous
Jefferies Healthcare Conference
CEO Erik Manting will participate.
Learn more
11 November 2022Previous
Publication of Q3 2022 Results
Mendus will publish the results of the third quarter of 2022 on November 11th, 2022 at 8am CET.
Learn more
8 November 2022Previous
Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Director Research Satwinder Kaur Singh and Director Business Development Céline Hechard will participate.
Learn more
27 October 2022Previous
European Society of Gynecological Oncology Congress
Initial clinical results from the ALISON trial were accepted for presentation at the European Society of Gynecological Oncology (ESGO) congress.
Learn more
24 October 2022Previous
BIO-Europe
Mendus CEO Erik Manting and Director Business Development Céline Hechard will participate in the partnering conference.
Learn more
12 October 2022Previous
Edison Oncology ABCs – Vaccines: Niche no longer
Mendus CMO Jeroen Rovers participated in an expert panel webcast organized by Edison Group.
Learn more
28 September 2022Previous
Next Frontiers in Cancer Vaccines
Mendus CEO Erik Manting will present on September 28th, 2022 at 3:10 pm CET at the event organized by HollandBIO and the Oncode Institute.
Learn more